TD Cowen Issues Positive Forecast for Natera (NASDAQ:NTRA) Stock Price

Natera (NASDAQ:NTRA) had its price target boosted by equities research analysts at TD Cowen from $155.00 to $175.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the medical research company’s stock. TD Cowen’s price target suggests a potential upside of 5.75% from the company’s previous close.

Other analysts have also issued research reports about the stock. Canaccord Genuity Group lifted their target price on shares of Natera from $150.00 to $165.00 and gave the company a “buy” rating in a research report on Wednesday. Craig Hallum boosted their target price on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday. Morgan Stanley raised their price objective on shares of Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. The Goldman Sachs Group upped their price objective on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $150.00 price objective on shares of Natera in a research report on Friday, September 13th. One analyst has rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and an average price target of $135.06.

Natera Stock Performance

NASDAQ:NTRA traded up $30.37 during trading hours on Wednesday, reaching $165.49. The company had a trading volume of 2,689,452 shares, compared to its average volume of 1,319,496. Natera has a 1-year low of $49.97 and a 1-year high of $167.79. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The firm has a market cap of $20.47 billion, a PE ratio of -94.03 and a beta of 1.53. The business’s 50 day moving average price is $125.09 and its 200-day moving average price is $114.52.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.88% and a negative net margin of 14.01%. The business had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. During the same period in the previous year, the business earned ($0.95) earnings per share. The business’s revenue was up 63.9% compared to the same quarter last year. Research analysts forecast that Natera will post -1.96 EPS for the current year.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 5,583 shares of the company’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $118.91, for a total value of $663,874.53. Following the completion of the sale, the chief executive officer now directly owns 200,710 shares in the company, valued at approximately $23,866,426.10. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CEO Steven Leonard Chapman sold 5,583 shares of Natera stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $118.91, for a total value of $663,874.53. Following the transaction, the chief executive officer now owns 200,710 shares of the company’s stock, valued at $23,866,426.10. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Michael Burkes Brophy sold 608 shares of the company’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $120.76, for a total transaction of $73,422.08. Following the sale, the chief financial officer now directly owns 74,014 shares of the company’s stock, valued at approximately $8,937,930.64. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,464 shares of company stock valued at $5,849,977. 7.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Natera

Hedge funds have recently added to or reduced their stakes in the business. Brooklyn Investment Group bought a new stake in shares of Natera in the third quarter valued at approximately $70,000. Millrace Asset Group Inc. raised its stake in Natera by 22.5% during the 3rd quarter. Millrace Asset Group Inc. now owns 12,144 shares of the medical research company’s stock valued at $1,542,000 after purchasing an additional 2,228 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Natera by 87.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 67,906 shares of the medical research company’s stock valued at $8,621,000 after purchasing an additional 31,649 shares during the period. Harvest Fund Management Co. Ltd grew its position in Natera by 90.7% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 7,774 shares of the medical research company’s stock worth $987,000 after purchasing an additional 3,697 shares during the last quarter. Finally, Daiwa Securities Group Inc. bought a new position in shares of Natera during the 3rd quarter worth about $232,000. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.